CO-1686 hydrobromide

    • 货号:MC1005
      • CasNo:
      • 1446700-26-0
      • 分子式:
      • C27H29BrF3N7O3
      • 纯度:
      • >98%
      • 靶点:
      • EGFR
      • IC50:
      • IC50: 21.5 nM (EGFRL858R/T790M), 303.3 nM (EGFRWT)
      • 体外研究:
      • CO-1686 (0.1 μM) inhibits EGFR potently and irreversibly, and inhibits more than 50% of 23 targets. CO-1686 potently and selectively inhibits growth of NSCLC cells expressing mutant EGFR and induces apoptosis. CO-1686 resistant NSCLC cell lines are sensitive to AKT inhibition[1].
      • 体内研究:
      • CO-1686 (100 mg/kg/day, p.o.) demonstrates anti-tumor activity in NSCLC EGFR mutant xenograft models. CO-1686 (50 mg/kg bid, p.o.) demonstrates anti-tumor activity in human EGFR-L858R and EGFR-L858R-T790M expressing transgenic mice[1].
      • 简介:
      • CO-1686 hydrobromide is a novel, irreversible and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M (IC50=21 nM).
      • 特异性:
      • TargetTargets the mutant forms of EGFR including T790M (IC50=21 nM).
      • 来源:
      • Rabbit
      • 稀释:
      • IC50: 21.5 nM (EGFRL858R/T790M), 303.3 nM (EGFRWT)
      • 浓度:
      • >98%
      • 储存:
      • 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO
      • 其他名称:
      • Rociletinib hydrobromide; AVL-301 hydrobromide; CNX-419 hydrobromide
      • 分子量:
      • 636.46
      • 产品图片